Loading...
XLON
GSK
Market cap99bUSD
Oct 30, Last price  
1,855.00GBP
1D
2.26%
1Q
-3.96%
Jan 2017
17.57%
Name

GSK plc

Chart & performance

D1W1MN
XLON:GSK chart
P/E
13.00
P/S
2.28
EPS
1.43
Vol. 1Y
24.78%
Shs. 5Y
-12.57%
Rev. 5Y
-0.85%
Div Yld LY
3.45%
Div Yld TTM
3.67%
Revenues
32.67b
+4.11%
23,656,048,00022,716,000,00024,352,000,00028,368,000,00028,392,000,00027,387,000,00026,431,000,00026,505,000,00023,006,000,00023,923,000,00027,889,000,00030,186,000,00030,821,000,00033,754,000,00034,099,000,00034,114,000,00029,324,000,00030,328,000,00031,376,000,00032,667,000,000
Net income
5.72b
+121.98%
5,389,000,0005,214,000,0004,712,000,0005,531,000,0001,634,000,0005,261,000,0004,565,000,0005,436,000,0002,756,000,0008,422,000,000912,000,0001,532,000,0003,623,000,0004,645,000,0005,749,000,0004,385,000,00014,956,000,0004,928,000,0002,575,000,0005,716,000,000
CFO
7.14b
+8.99%
4,336,008,4506,045,436,0007,311,000,0007,841,000,0006,220,200,5686,250,000,0004,375,000,0007,222,000,0005,176,000,0002,569,000,0006,497,000,0006,918,000,0008,421,000,0008,020,000,0008,441,000,0007,952,000,0007,403,000,0006,768,000,0006,554,000,0007,142,957,939
Dividend
Nov 12, 202617 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

GSK plc, a global healthcare and pharmaceutical leader with roots tracing back to 1715, is headquartered in Brentford, United Kingdom. Operating extensively across the UK, United States, and other international markets, its activities span the entire lifecycle of healthcare products, encompassing research, development, manufacturing, and commercialization. Its broad portfolio includes pharmaceuticals, vaccines, over-the-counter medications, and a range of health-focused consumer products. The company operates through four primary divisions: Pharmaceuticals, Pharmaceutical Research & Development, Vaccines, and Consumer Healthcare. Within its pharmaceutical arm, GSK provides therapeutic solutions for a broad spectrum of conditions. These include ailments in respiratory health, HIV, immuno-inflammation, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital issues, metabolic diseases, bacterial infections, and dermatology. The consumer healthcare division delivers products across wellness, oral health, nutrition, and skin health categories. These are available in numerous formats, including nasal sprays, tablets, syrups, lozenges, gum and transdermal patches, caplets, infant syrup drops, liquid suspensions, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams, non-medicated patches, lip balms, gummies, and soft chews. GSK also maintains collaborative agreements with various organizations such as 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Furthermore, strategic partnerships are in place with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The firm, known as GlaxoSmithKline plc until its name change to GSK plc in May 2022, embodies centuries of innovation in healthcare.

Related entities

Subsidiaries (54)
14245563 CANADA INC.
BELLUS HEALTH INC.
BURROUGHS WELLCOME INTERNATIONAL LIMITED
CORIXA CORPORATION
ESKAYLAB LIMITED
GLAXO GROUP LIMITED
GLAXO OPERATIONS UK LIMITED
GLAXO WELLCOME PRODUCTION
GLAXO WELLCOME SA
GLAXO WELLCOME UK LIMITED
GLAXOSMITHKLINE BIOLOGICALS
GLAXOSMITHKLINE BIOLOGICALS KFT.
GLAXOSMITHKLINE CAPITAL INC.
GLAXOSMITHKLINE HOLDINGS LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED
GLAXOSMITHKLINE LIMITED
GLAXOSMITHKLINE LLC
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
GLAXOSMITHKLINE SERVICES UNLIMITED

Key people

Chief Financial Officer, Executive Director · since 2023
President - Corporate Development · since 2022
Regis Simard
President - Global Supply Chain · since 2022
Phil Thomson
President - Global Affairs · since 2017
Deborah Waterhouse
Chief Executive Officer, ViiV Healthcare and President - GSK Global Health · since 2022
Diana Conrad
Chief People Officer · since 2019
Sally Jackson
Senior Vice President - Global Communications and CEO Office · since 2019
Shobie Ramakrishnan
Chief Digital and Technology Officer · since 2021
Tony Wood
Chief Scientific Officer · since 2024
James Ford
Senior Vice President, Group General Counsel, Legal and Compliance · since 2018
Luke Miels
Chief Executive Officer - Designate, Director · since 2026
Company Secretary · since 2011
Non-Executive Director · since 2022
Gavin Screaton
Non-Executive Director · since 2025
Independent Non-Executive Chairman of the Board · since 2019
Independent Non-Executive Director · since 2022
Senior Independent Non-Executive Director · since 2022
Anne Beal
Independent Non-Executive Director · since 2021
Non-Executive Independent Director · since 2023
Harry Dietz
Independent Non-Executive Director, Scientific and Medical Expert · since 2022
IPO date
May 22, 1972
Employees
69,400
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
79 NEW OXFORD STREET
LONDON, LND WC1A 1DG
GB
Previous name
GLAXOSMITHKLINE PLC

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT